Polyhydroxy Patents (Class 514/669)
  • Publication number: 20150126564
    Abstract: The present invention relates to compounds and methods for the prevention or treatment of infections by negative strand RNA viruses, such as influenza virus and measles virus, wherein said compounds delay or inhibit viral replication by modulating the level or activity of a polypeptide involved in the synthesis or degradation of sphingosine-1-phosphate (S1P) in a cell, tissue, or subject. The methods involve administration of one or more compounds which modulate the level of gene expression, where the gene encodes a polypeptide involved in regulating the metabolic level of S1P, or modulate the level or activity of a polypeptide involved in regulating the metabolic level of S1P, such as sphingosine kinase (SK) and S1P lyase (SPL). Exemplary methods are directed towards reducing the level of SW by reducing the level or activity of one or more SKs, increasing the level or activity of one or more SPLs, or a combination of both steps.
    Type: Application
    Filed: May 31, 2012
    Publication date: May 7, 2015
    Applicant: The Curators of the University of Missouri
    Inventors: Bumsuk Hahm, Young-Jin Seo, Stephen Alexander, Vijayan Madhuvanthi
  • Patent number: 8987304
    Abstract: The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A) or the like, wherein R3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: March 24, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Makoto Matsumoto, Hiroyuki Hashizume, Tatsuo Tomishige, Masanori Kawasaki, Yoshihiko Shimokawa
  • Publication number: 20150073003
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Arie DAGAN, Shimon SLAVIN, Shimon GATT, Jeremy ZAHAVY
  • Publication number: 20150051207
    Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. The invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 19, 2015
    Inventors: Julie D. Saba, Henrik Fyrst, Robert Bittman
  • Publication number: 20140309275
    Abstract: The disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing disease. In certain embodiments, the disclosure relates to methods of treating an infection or cancer comprising administering a pharmaceutical composition disclosed herein to a subject in need thereof. In a typical embodiment, one administers a pharmaceutical composition comprising sphingosine or a sphingosine analog to a subject at risk for, exhibiting symptoms of or diagnosed with a malaria infection.
    Type: Application
    Filed: September 27, 2012
    Publication date: October 16, 2014
    Inventors: Dennis C. Liotta, Jason Holt, JR., Michael G. Natchus, Mark T. Baillie, Eric J. Miller, Mary R. Galinski
  • Patent number: 8834943
    Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: September 16, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Michael Southall, Katharine Martin, Phyllis Mitchell, Menas Kizoulis, Neena Tierney, Elvin R. Lukenbach, Binoy K. Bordoloi
  • Publication number: 20140256664
    Abstract: The present application discloses rapid Mycobacterium tuberculosis drug susceptibility utilizing real-time PCR of mycobacteriophage D29 DNA. One protocol involves culturing Tb isolates for 48 hours with and without drugs at critical concentrations, followed by incubation with 103 pfu/ml of D29 mycobacteriophage for 24 hours and then real-time PCR. Many drugs can be incubated instantly with Tb and phage. The change in phage DNA real-time PCR cycle threshold (Ct) between control Tb and Tb treated with drugs was calculated and correlated with conventional agar proportion drug susceptibility results. Specifically, 9 susceptible clinical isolates, 22 MDR, and 1 XDR Tb strains were used and Ct control?Ct drug cutoffs of between +0.3 and ?6.0 yielded 422/429 (98%) accurate results for the drugs tested. The Ct values correlated with isolate minimal inhibitory concentration (MIC) for most agents. This D29 qPCR assay offers a rapid, accurate, 1-3 day phenotypic drug susceptibility test.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 11, 2014
    Applicant: University of Virginia Patent Foundation
    Inventors: Eric R. Houpt, Kimberly A. Kelly, Suporn Pholwat
  • Publication number: 20140255330
    Abstract: Novel mixtures of sugar amides or sugar amines are disclosed that have improved thermal properties over the individual components. New feedstocks based on both the surfactant tail as well as the sugar head group allow for improved physical properties of sugar amide surfactant mixtures and thus improved formulatability. Furthermore, new sources of unique methyl esters from both bioengineering and or co-metathesis of fats and oils provide novel and improved sugar amide surfactant mixtures.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: THE PROCTER & GAMBLE COMPANY
    Inventors: Scott Leroy Cron, Patrick Firmin Delplancke, Randall Thomas Reilman, Jeffrey John Scheibel, Melinda Phyllis Steffey, Phillip Kyle Vinson, Ryan Michael West
  • Patent number: 8822542
    Abstract: A method of treating and/or preventing oxidative damage, comprising administering an effective IsoK/NeuroK adduct formation suppressing amount of a phenolic amine compound and/or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: September 2, 2014
    Assignee: Vanderbilt University
    Inventors: L. Jackson Roberts, II, Jeffrey R. Balser, Sean S. Davies, Venkataraman Amarnath, Prakash C. Viswanathan
  • Publication number: 20140170067
    Abstract: The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.
    Type: Application
    Filed: August 16, 2012
    Publication date: June 19, 2014
    Applicant: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
    Inventors: Guenter Haufe, Bodo Levkau, Michael Schaefers, Stefani Silke Schilson, Petra Keul
  • Publication number: 20140170092
    Abstract: The invention relates to the use of sphinganine for improving the visual appearance of skin and hair, for caring for, for protecting and/or for stimulating the growth of skin and hair.
    Type: Application
    Filed: July 4, 2012
    Publication date: June 19, 2014
    Applicant: EVONIK DEGUSSA GMBH
    Inventors: Mike Farwick, Tim Koehler, Matthias Mentel
  • Patent number: 8722113
    Abstract: The present invention relates to compositions comprising a Southernwood extract and an amine compound, and methods treating skin with said compositions.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: May 13, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Michael Anthonavage, Meghan Russell, Samantha Tucker-Samaras
  • Publication number: 20140127294
    Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
    Type: Application
    Filed: April 10, 2012
    Publication date: May 8, 2014
    Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Maojian Gu, Qilan Zheng, Chao Xu, Ning Li, Guixian Chen, Lan Zheng, Min Wang, Lintao Jiang
  • Publication number: 20140086857
    Abstract: Compositions comprising siloxane polymers are disclosed. The compositions are useful as thixotropic bases for a variety of components, such as antimicrobial agents, sterilants, medicaments, antibiotics, analgesics, essential oils, preservatives, colorants, fragrances, and the like. Methods for preparing the compositions are also disclosed.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicant: QUADSIL, INC.
    Inventor: John D. Blizzard
  • Publication number: 20140045947
    Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 13, 2014
    Applicant: Dynamis Therapeutics, Inc.
    Inventor: Annette Tobia
  • Patent number: 8618179
    Abstract: The present invention relates to a composition comprising a pesticide and an alkoxylate. Moreover, the invention relates to the alkoxylate, to a process for its preparation and to its use as adjuvant in pesticide-comprising spray mixtures. The invention furthermore relates to a method of controlling phytopathogenic fungi and/or undesired vegetation and/or undesired insect or mite attack and/or for regulating the growth of plants, wherein the composition is allowed to act on the respective pests, their environment or the plants to be protected from the respective pest, on the soil and/or on undesirable plants and/or the crop plants and/or their environment. Furthermore, the invention relates to seed comprising the composition.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: December 31, 2013
    Assignee: BASF SE
    Inventors: Paul Klingelhoefer, Arend Jouke Kingma, Sophie Vogel, Kevin Huyghe, Gerd Haderlein, Gerhard Schnabel, Marc Nolte, Richard Roger Evans
  • Publication number: 20130338059
    Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.
    Type: Application
    Filed: December 22, 2011
    Publication date: December 19, 2013
    Applicant: Centre Hospitalier Universitaire Vaudois
    Inventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
  • Publication number: 20130231305
    Abstract: The present invention relates to a method of modulating cellular activity. More particularly, the present invention provides a method of modulating apoptosis by modulating protein 14-3-3 phosphorylation and, thereby its functionality. The present invention still further extends to methods for identifying agents capable of modulating protein 14-3-3 phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted cellular activity, such as unwanted cell survival.
    Type: Application
    Filed: March 29, 2011
    Publication date: September 5, 2013
    Applicant: Medvet Science Pty. Ltd.
    Inventors: Joanna Woodcock, Stuart Pitson, Angel Lopez
  • Patent number: 8518450
    Abstract: The invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier, blending the drug to be delivered into one of the emulsion phases, doping either the oil-phase or the outer-water phase with a carbohydrate, and spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm, which nanoparticles are substantially spherical.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: August 27, 2013
    Assignee: CSIR
    Inventor: Lonji Kalombo
  • Patent number: 8518996
    Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 27, 2013
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Tomoko Fujimoto
  • Publication number: 20130217691
    Abstract: A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-increasing retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) compounds selected from the groups consisting of (i) a non-18 carbon chain length L-threo-sphinganine(s) or pharmaceuticeutically acceptable salt thereof, (ii) glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor(s), and (iii) sphingomyelin or dihydrosphingomyelin synthase inhibitor(s). Preferred L-threo-sphinganines are of carbon chain length 17 carbons, 19 carbons and 20 carbons. A preferred glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingomyelin or dihydrosphingomyelin synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 22, 2013
    Applicant: Texas Tech University System
    Inventor: Texas Tech University System
  • Publication number: 20130217780
    Abstract: The invention relates to a biostatic neutralizing composition for aqueous fluids, including two amines, one of which is dihydroxyethylamine. The invention also relates to the use of such a composition as a biostatic neutralizing additive for industrial aqueous fluids. The invention further relates to the industrial aqueous fluids containing such a composition.
    Type: Application
    Filed: September 27, 2011
    Publication date: August 22, 2013
    Applicant: Arkema France
    Inventor: Jean-Pierre Lallier
  • Publication number: 20130190401
    Abstract: This invention relates to the use of an active compound selected from the group comprising a sphingoid base, a sphingoid base derivative or a mixture of two or more these compounds for manufacturing a cosmetic composition suitable for topical application with animals having an at least partly fur covered skin for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur.
    Type: Application
    Filed: July 20, 2012
    Publication date: July 25, 2013
    Applicant: DERMACONCEPT JMC
    Inventors: Jean-Claude ALLART, Jean-Marie LEFEVRE, Jacques PEYROT
  • Publication number: 20130108675
    Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 2, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Patent number: 8426474
    Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: April 23, 2013
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard Farng, Steven Mrha
  • Patent number: 8415397
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 9, 2013
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Publication number: 20130045941
    Abstract: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.
    Type: Application
    Filed: October 29, 2010
    Publication date: February 21, 2013
    Applicant: Abela Pharmaceuticals, Inc.
    Inventors: Colette Cozean, Rodney Benjamin, Anthony Keller, Jeff Varelman
  • Patent number: 8344031
    Abstract: The present invention features a method of treating at least one sign of aging on the skin selected from the group consisting of enhancing the elasticity of said skin, enhancing the firmness of said skin, and reducing the appearance of wrinkles or cellulite on the skin, by administering to skin in need of such treatment a composition comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: January 1, 2013
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Eduardo Ruvolo, Michael D. Southall, Binoy K. Bordoloi, Elvin R. Lukenbach, Gloria Jean Lukenbach, legal representative
  • Publication number: 20120329737
    Abstract: The invention relates to hybrid molecules made of two lipids or lipid-analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the hybrid molecule. The hybrid molecules according to the invention can be used as pharmaceutical or as a cosmetic preparation.
    Type: Application
    Filed: June 23, 2010
    Publication date: December 27, 2012
    Inventor: Hans-Uwe Wolf
  • Patent number: 8338338
    Abstract: The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising fungicidal triazoles. It also relates to formulations comprising one or more fungicidal triazoles and alkoxylated amines. These formulations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, biodegradable material and textiles against deterioration due to the action of fungi.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: December 25, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Johannes Geradus Thiedink, Emmanueal Philippe Thierry Paris, Mark Arthur Josepha Van der Flaas
  • Patent number: 8329685
    Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: December 11, 2012
    Assignee: North West University
    Inventor: Petrus Johannes Meyer
  • Publication number: 20120301422
    Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.
    Type: Application
    Filed: January 16, 2003
    Publication date: November 29, 2012
    Inventor: Petrus Johannes Meyer
  • Patent number: 8282952
    Abstract: The invention relates to insect attractants containing compounds with pentagonal heterocyclic structures that are effective in attracting fruitflies.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: October 9, 2012
    Assignee: Activetrad (Proprietary) Limited
    Inventor: Christoffel J. Smit
  • Publication number: 20120251560
    Abstract: The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R3 and R4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.
    Type: Application
    Filed: March 23, 2012
    Publication date: October 4, 2012
    Applicant: Massachusetts Institute of Technology
    Inventors: James E. Dahlman, Avraham D. Schroeder, Daniel Griffith Anderson, Robert S. Langer, Christopher G. Levins
  • Patent number: 8278359
    Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof for treating acne and reducing the appearance of oil or pores on the skin.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: October 2, 2012
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Michael Southall, Katharine Martin, Elvin R. Lukenbach, Binoy K. Bordoloi, Menas Kizoulis, Apostolos Pappas, Catherine Stubler Salerno
  • Publication number: 20120245107
    Abstract: The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents.
    Type: Application
    Filed: June 7, 2012
    Publication date: September 27, 2012
    Inventors: William Henry, Henk-Andre Kroon, Linda Summerton
  • Patent number: 8268805
    Abstract: The invention relates to the use, as agent for depigmenting and/or whitening the skin, in particular for eliminating pigmentary spots and/or senescence spots, and/or as anti-browning agents, of a compound of formula (I): R1—CHOH—CH(NH—COR2)(CH2OH)??(I) in which R1 denotes a C11 to C21 alkyl radical, and R2 denotes a linear, optionally hydroxylated C11-C19 hydrocarbon-based radical, with the hydroxyl group being in the alpha-position with respect to the carbonyl, which may comprise one or more ethylenic unsaturations, in particular one or two ethylenic unsaturations. The invention also relates to a cosmetic process for depigmenting and/or lightening skin exhibiting pigmentation spots, comprising the application to the skin of a composition comprising, in a physiologically acceptable medium, a compound of formula (I).
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: September 18, 2012
    Assignee: L'Oreal
    Inventors: Pascale Pelletier, Catherine Marion
  • Publication number: 20120148604
    Abstract: The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.
    Type: Application
    Filed: August 20, 2010
    Publication date: June 14, 2012
    Applicant: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • Patent number: 8163313
    Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: April 24, 2012
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Michael Southall, Katharine Martin, Phyllis Mitchell, Menas Kizoulis, Neena Tierney, Elvin R. Lukenbach, Binoy K. Bordoloi
  • Publication number: 20120071446
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage or at a daily dosage lower than the standard daily dosage.
    Type: Application
    Filed: November 22, 2011
    Publication date: March 22, 2012
    Inventors: John M. KOVARIK, Silke Appel-Dingemanse
  • Publication number: 20120053134
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases, and more particularly, to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases containing, as active ingredients, any one or two or more compounds selected from a group consisting of the compound of chemical formula 1, the compound of chemical formula 2, and the acceptable salts thereof. The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia.
    Type: Application
    Filed: May 6, 2010
    Publication date: March 1, 2012
    Inventors: Jae-Hoon Jung, Hyung-Ryong Moon
  • Publication number: 20120052120
    Abstract: Embodiments of the present invention are directed to articles of manufacture, spheres having a diameter of 50 to 500 nanometers which contain poorly soluble drugs and methods of making such spheres. Embodiments of the present invention have particular application for the following drug candidates and closely related poorly soluble derivatives of such candidates: (i) indole hydrazinecarbothioamide [NSC 73306]; (ii) fenretinide (4HPR) [NSC 374551]; (iii) safingol [NSC 714503]; (iv) 17-allylamino demethoxygeldanamycin (17-AAG) [NSC 330507]; and (v) an aminoflavone drug [NSC 686288].
    Type: Application
    Filed: August 23, 2011
    Publication date: March 1, 2012
    Inventor: Trevor Percival CASTOR
  • Publication number: 20110294874
    Abstract: The invention relates to the treatment and diagnosis of organ dysfunction caused by ischemia reperfusion injury. In particular, the invention relates to sphinganine-1-phosphate, a sphingolipid metabolite, and its use in the diagnosing, preventing, and/or treating ischemia reperfusion-associated disorders, including, without limitation, disorders of the kidney, liver, lung, brain, and heart.
    Type: Application
    Filed: December 9, 2009
    Publication date: December 1, 2011
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: H. Thomas Lee, Mihwa Kim
  • Publication number: 20110287083
    Abstract: Bioabsorbable compositions of A) blends of bioabsorbable homopolymers and/or copolymers containing glycolide and lactide and B) salts of fatty acids and/or fatty acid esters are described. Processes for making the compositions and surgical articles made totally or in part therefrom, including suture coatings, are also described.
    Type: Application
    Filed: July 21, 2011
    Publication date: November 24, 2011
    Applicant: Tyco Healthcare Group LP
    Inventor: Ahmad R. Hadba
  • Publication number: 20110263714
    Abstract: The reverse vesicle composition of the present invention includes (A) a sphingosine represented by formula (1) (wherein R1 represents a C4 to C30 linear alkyl group which may be substituted by a hydroxyl group, a carbonyl group, or an amino group; Y represents a methylene group, a methine group, or an oxygen atom; each of X1, X2, and X3 represents a hydrogen atom, a hydroxyl group, or an acetoxy group; X4 represents a hydrogen atom, an acetyl group, or a glyceryl group, or forms an oxo group together with the adjacent oxygen atom (wherein when Y is a methine group, one of X1 and X2 is a hydrogen atom, and the other is absent, and when X4 forms an oxo group, X3 is absent); each of R2 and R3 represents a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; a is a number of 2 or 3; each of (R)a represents a hydrogen atom, an amidino group, or a linear-chain alkyl group optionally having a substituent selected from among a hydroxyl group, a hydroxyalkoxy group, an alkoxy group, and a
    Type: Application
    Filed: August 8, 2008
    Publication date: October 27, 2011
    Applicant: Kao Corporation
    Inventor: Koji Okubo
  • Publication number: 20110251289
    Abstract: The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza-undecane-2,4,8,10-tetraol.
    Type: Application
    Filed: June 3, 2009
    Publication date: October 13, 2011
    Applicants: CSIR, AGRICULTURAL RESEARCH COUNCIL, UNIVERSITY OF PRETORIA
    Inventors: Moira Bode, Robert Vleggaar, Paul J. Gates, R. Anitra Schultz, Dharmaral Naicker, Nel Fourie
  • Publication number: 20110229565
    Abstract: This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs.
    Type: Application
    Filed: September 17, 2009
    Publication date: September 22, 2011
    Inventors: Jeffrey M. Karp, Praveen Kumar Vemula, George John, Greg Cruikshank
  • Publication number: 20110217247
    Abstract: The present invention provides novel topically-applied skin and face coating and paint compositions comprising near infrared reflecting pigments and hydrogels swollen with aqueous solution and/or with simulated sweat. The invention further provides methods of making and using the compositions. The novel compositions protect the skin of the wearer from damage due to intense external heat or thermal flux and simultaneously divert thermal energy to a complementary evaporative cooling mechanism. The compositions protect skin from external thermal fluxes, conform to skin chemistry, and are easy to apply and remove.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 8, 2011
    Inventors: Robert Yeats Lochhead, Janice Paige Buchanan, Laura Lynn Anderson, Nicole Marie Mackey
  • Publication number: 20110189307
    Abstract: Methods and compositions for treating wounds, decubitus ulcers, diaper rash, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates in one embodiment the use of an aqueous or emollient medium having one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface.
    Type: Application
    Filed: February 4, 2010
    Publication date: August 4, 2011
    Inventor: JENNIFER BARTELS
  • Publication number: 20110184065
    Abstract: Use of spongosine (2-methoxyadenosine) as an analgesic, in particular for the treatment of hyperalgesia, is described.
    Type: Application
    Filed: August 20, 2010
    Publication date: July 28, 2011
    Inventor: Peter Richardson